Af­ter a sharp plunge, Epizyme bounces back on some bon­ny fore­casts as shares go on a roller coast­er ride

Yes­ter­day I re­port­ed that Epizyme shares $EPZM took a dive af­ter the com­pa­ny re­port­ed some dis­ap­point­ing da­ta on its DL­B­CL group in an on­go­ing Phase II study of tazeme­to­stat.

But that was just the scary start to a roller coast­er ride that saw the stock shoot back up as an­a­lysts of­fered a thumbs up for oth­er out­comes that have a more up­beat tone.

Leerink’s Ge­of­frey Porges called tazeme­to­stat “one of the most in­trigu­ing small mol­e­cules in the ma­lig­nan­cy field.” He added:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER